Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403.

Abstract

The orally active serine protease inhibitor ONO-3403 is an analog of FOY-3403 that has more potent protease-inhibitory activity. In the present study, oral administration of ONO-3403 was used to challenge 3-methylcholanthrene-induced carcinoma. This drug was administered 3 times daily for 9 weeks via a stomach tube at a dose of 10 mg/kg in a 1-ml volume in 6 mice harboring solid tumors. This protease inhibitor significantly inhibited tumor growth (p<0.001) and prolonged survival-time (p<0.01). These results indicated that oral administration of the potent serine protease inhibitor ONO-3403 has an antitumor effect on malignant tumors.

• Authors: Motohiro Ohkoshi, Satoru Okuda
• Journal: Anticancer research (Anticancer Res) 2002 Mar-Apr Vol. 22 Issue 2A Pg. 821-3 ISSN: 0250-7005 [Print] Greece
• PMID: 12014657 (Publication Type: Journal Article)

Chemical References

• Benzamidines
• Growth Inhibitors
• Serine Proteinase Inhibitors
• ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate
• Allylglycine

Topics

• Administration, Oral
• Allylglycine (analogs & derivatives, pharmacology)
• Animals
• Benzamidines (pharmacology)
• Body Weight (drug effects)
• Carcinoma, Squamous Cell (drug therapy, pathology)
• Cell Division (drug effects)
• Female
• Growth Inhibitors (pharmacology)
• Mice
• Serine Proteinase Inhibitors (pharmacology)
• Skin Neoplasms (drug therapy, pathology)